Mediators of Inflammation · 2023 · 13 citations · 29 references
MedicineEndocrinologyPharmacologyBone MetabolismInflammationPeri-implant DiseasesBone EndocrinologyBone HealthBone Metabolism DisordersBone Metabolism PharmacotherapyOsteoblast BiologyOsteoblast FunctionAdvanced Glycation End ProductsBone Resorption InhibitionBone Resorption MarkersMicrocomputed TomographyMicrocomputed Tomography AnalysisNf-κb SignalingRankl SignalingRankl-mediated Bone Destruction
In this study, we examined the effect of the GP130-targeting molecule, LMT-28, on lipopolysaccharide- (LPS-) induced bone resorption around implants in diabetic models using in vitro and rat animal experiments. First, LMT-28 was added to osteoblasts stimulated by LPS and advanced glycation end products (AGEs), and nuclear factor-κB receptor-activating factor ligand (RANKL) and associated pathways were evaluated. Then, LMT-28 was administered by gavage at 0.23 mg/kg once every 5 days for 2 weeks to type 2 diabetic rats with peri-implantitis induced by LPS injection and silk ligature. The expression of IL-6 and RANKL was evaluated by immunohistochemistry, and the bone resorption around implants was evaluated by microcomputed tomography. The results showed that LMT-28 downregulated the expression of RANKL through the JAK2/STAT3 signaling pathway in osteoblasts stimulated by LPS and AGEs, reduced bone resorption around implants with peri-implantitis, decreased the expression of IL-6 and RANKL, and decreased osteoclast activity in type 2 diabetic rats. This study confirmed the ability of LMT-28 to reduce LPS-induced bone resorption around implants in diabetic rats.
29
Py Palmqvist, Emma Persson, H. Herschel Conaway et al. · The Journal of Immunology · 2002 · 491 citations · Full text
Interleukin-6 and interleukin-11 support human osteoclast formation by a RANKL-independent mechanism
O Kudo, A Sabokbar, A. Pocock et al. · Bone · 2003 · 468 citations
Medicine, Cell Biology, Immunology +14